MetaCap

BridgeBio Pharma Inc. Company Profile

NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

76.03-2.15 (-2.75%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BridgeBio Pharma at a glance

BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Palo Alto, CA. BridgeBio Pharma is led by Dr. Neil Kumar Ph.D. and employs about 1,081 people. The company's shares have traded publicly since 2019.

At a market capitalization of $14.81 billion, it is considered a large-cap company. Its SEC Central Index Key (CIK) is 0001743881, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does BridgeBio Pharma do?

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Business description based on the company's public filings.

Company information

Legal name
BridgeBio Pharma Inc.
Ticker
NASDAQ: BBIO
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Neil Kumar Ph.D.
Employees
1,081
Headquarters
3160 Porter Drive, Palo Alto, CA, United States
Phone
650 391 9740
IPO year
2019
Market cap
$14.81B
SEC CIK
0001743881

Companies similar to BridgeBio Pharma

BBIO peer companies
CompanyPrice% ChgMarket capCompare
JAZZJazz Pharmaceuticals plc230.26-2.62%$14.78Bvs BBIO
ASNDAscendis Pharma A/S252.73-1.26%$16.58Bvs BBIO
ELANElanco Animal Health Incorporated25.74-2.09%$12.87Bvs BBIO
RDYDr. Reddy's Laboratories Ltd14.89+0.40%$12.41Bvs BBIO
BMRNBioMarin Pharmaceutical Inc.60.41-1.64%$11.70Bvs BBIO
ALNYAlnylam Pharmaceuticals Inc.143.82-2.71%$19.26Bvs BBIO
TGTXTG Therapeutics Inc.63.34-2.37%$9.57Bvs BBIO
SYRESpyre Therapeutics Inc.93.47-4.26%$8.88Bvs BBIO

Related